Mesupron: Final Phase II data

Final data from an open-label, European Phase II trial in 95 patients with locally advanced, inoperable, non-metastatic pancreatic cancer showed that 200 and 400 mg daily oral Mesupron plus weekly IV Gemzar gemcitabine led to overall response rates (ORRs) of 7.1% and 12.9%, respectively, vs. 3.8% for Gemzar alone, and tumor response rates, defined as tumor shrinkage >30%, of 21.4% and 35.5% vs. 15.4% for Gemzar alone. Median PFS for low- and high-dose Mesupron plus Gemzar was 24 and 35.7 weeks, respectively, vs. 35.3 weeks for Gemzar alone, with 12-month PFS rates of 22.5% and 26.9% vs. 16.2% for Gemzar alone. Median OS for low- and high-dose Mesupron plus Gemzar was 9.7 and 12.5 months, respectively, vs. 9.9 months for Gemzar alone, with 12-month OS rates of 40.7% and 50.6% vs. 33.9% for Gemzar alone. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...